|Televised News Report Lifts Shares of Touted Omega 3 Fatty Acids Stock|
|By Staff and Wire Reports|
|Friday, 21 September 2012 19:01|
In the segment, Dr. Sampalis shed light on the key differences between krill and fish oil, emphasizing some of the advantages of krill based Omega 3 fatty acids.
Said Sampalis : "Krill, even though it has the same amount of Omega 3's as fish oil, it is better digested, a lot better absorbed and a lot better used by the body."
Prices for shares of Neptune, Amarin Corporation (NASDAQ: AMRN) and others had been affected adversely following the recent study, but analysts at Leerink Swann reiterated an "outperform" rating on shares of Amarin, maintaining their $27 price target in a research note to investors.
According to the note, Amarin's management continues to believe the firm's FDA approved Vascepa has a decent chance of obtaining exclusivity on their new chemical entity.
Meanwhile, analysts at Roth Capital recently reiterated their Buy rating and $10.30 price target for shares of Neptune based on the revenue growth potential for the multiple krill oil initiatives. That banking firm believes Neptune warrants a higher valuation after seeing the growth and increasing demand for Neptune Krill Oil (NKO) in several territories, a strong IP position, and a key potential catalyst with clinical data read-out later this year from subsidiary Acasti Pharma's (TSX.V:APO) program for CaPre® for the treatment of Hypertriglyceridemia.